Adjuvant chemotherapy outcomes of node negative, T1a, T1b, T1c hormone receptor-negative HER2-positive breast cancer patients

被引：0
|
作者：
Paul, Anu
Shi, Runhua
Peddi, Prakash
Burton, Gary
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-2761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2761
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
    Cancello, G.
    Maisonneuve, P.
    Rotmensz, N.
    Viale, G.
    Mastropasqua, M. G.
    Pruneri, G.
    Montagna, E.
    Dellapasqua, S.
    Iorfida, M.
    Cardillo, A.
    Veronesi, P.
    Luini, A.
    Intra, M.
    Gentilini, O.
    Scarano, E.
    Goldhirsch, A.
    Colleoni, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) : 713 - 720
  • [22] Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
    Cancello, G.
    Maisonneuve, P.
    Rotmensz, N.
    Viale, G.
    Mastropasqua, M. G.
    Pruneri, G.
    Montagna, E.
    Dellapasqua, S.
    Iorfida, M.
    Cardillo, A.
    Veronesi, P.
    Luini, A.
    Intra, M.
    Gentilini, O. D.
    Scarano, E.
    Pastrello, D.
    Goldhirsch, A.
    Colleoni, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Biological and Prognostic Role of Tumor Size (T1a, T1b, T1c) in Stage I Breast Cancer (Experience of International Cooperation)
    Kolyadina, I. V.
    Poddubnaya, I. V.
    van de Velde, Cornelis J. H.
    Kuppen, Peter J. K.
    Bastiaannet, E.
    Komov, D. V.
    Karseladze, A. I.
    Ermilova, V. D.
    Vishnevskaya, Y. V.
    Frank, G. A.
    SOVREMENNYE TEHNOLOGII V MEDICINE, 2014, 6 (03) : 28 - 34
  • [24] Role of axillary node dissection in patients with T1a and T1b breast cancer - Mayo Clinic experience
    Mincey, BA
    Bammer, T
    Atkinson, EJ
    Perez, EA
    ARCHIVES OF SURGERY, 2001, 136 (07) : 779 - 782
  • [25] Treatment of small (T1mic, T1a, and T1b) node-negative HER2+breast cancer - a review of current evidence for and against the use of anti-HER2 treatment regimens
    Johnson, Kai C. C.
    Quiroga, Dionisia
    Sudheendra, Preeti
    Wesolowski, Robert
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (05) : 505 - 522
  • [26] Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer
    He, Xuexin
    Ji, Jiali
    Tian, Mei
    Esteva, Francisco J.
    Hortobagyi, Gabriel N.
    Yeung, Sai-Ching Jim
    CLINICAL CANCER RESEARCH, 2019, 25 (24) : 7388 - 7395
  • [27] Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.
    Sharma, Priyanka
    Kimler, Bruce F.
    Klemp, Jennifer R.
    Ward, Claire
    Connor, Carol Sue
    McGinness, Marilee
    Matthew, Joshua
    Mammen, Varghise
    Wagner, Jamie Lynn
    Amin, Amanda Leigh
    Fabian, Carol J.
    Jensen, Roy A.
    Godwin, Andrew K.
    Khan, Qamar J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma
    Port, ER
    Tan, LK
    Borgen, PI
    Van Zee, KJ
    ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (01) : 23 - 27
  • [29] Contemporary management of patients with T1a and T1b prostate cancer
    Capitanio, Umberto
    CURRENT OPINION IN UROLOGY, 2011, 21 (03) : 252 - 256
  • [30] Incidence of axillary lymph node metastases in T1a and T1b breast carcinoma
    Elisa Rush Port
    Lee K. Tan
    Patrick I. Borgen
    Kimberly J. Van Zee
    Annals of Surgical Oncology, 1998, 5 : 23 - 27
12345